This report is a retrospective analysis of 27 patients who received Tacrolimus because of intol- erance or for refractoriness to Cyclosporin A (CyA) as prophylaxis against acute and chronic GvHD at a single institut...This report is a retrospective analysis of 27 patients who received Tacrolimus because of intol- erance or for refractoriness to Cyclosporin A (CyA) as prophylaxis against acute and chronic GvHD at a single institution. 9 patients were treated with Tacrolimus as acute GvHD developed despite optimal concentrations of CyA and 8 developed chronic GvHD despite continuation of CyA. 10 patients developed World Health Organisation Score (WHO) grade 2–3 toxicity to CyA. Overall 21 of 27 patients responded to Tacrolimus. Patients who underwent reduced conditioning responded as well as those patients who un- derwent conventional conditioning regimens. Tacrolimus is well tolerated and e?ective and might be an alternative primary agent for prevention of GvHD. Its role in reduced conditioning regimens needs to be further explored.展开更多
文摘This report is a retrospective analysis of 27 patients who received Tacrolimus because of intol- erance or for refractoriness to Cyclosporin A (CyA) as prophylaxis against acute and chronic GvHD at a single institution. 9 patients were treated with Tacrolimus as acute GvHD developed despite optimal concentrations of CyA and 8 developed chronic GvHD despite continuation of CyA. 10 patients developed World Health Organisation Score (WHO) grade 2–3 toxicity to CyA. Overall 21 of 27 patients responded to Tacrolimus. Patients who underwent reduced conditioning responded as well as those patients who un- derwent conventional conditioning regimens. Tacrolimus is well tolerated and e?ective and might be an alternative primary agent for prevention of GvHD. Its role in reduced conditioning regimens needs to be further explored.
